APG Asset Management N.V. Decreases Stake in Charles River Laboratories International, Inc. $CRL

Key Points

• APG Asset Management N.V. has reduced its stake in Charles River Laboratories by 9.3%, now owning 27,300 shares worth approximately $3.8 million.
• A significant increase in investment from other firms has been observed, with Assenagon Asset Management raising its position by 1,721.1%, now owning 570,097 shares valued at about $85.8 million.
• Charles River Laboratories stock recently showed a slight decline of 0.3%, with an average target price from analysts set at $175.69, indicating a consensus rating of "Hold."

APG Asset Management N.V. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 9.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,300 shares of the medical research company's stock after selling 2,804 shares during the quarter. APG Asset Management N.V. owned 0.06% of Charles River Laboratories International worth $3,804,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of CRL. Northwestern Mutual Wealth Management Co. raised its holdings in Charles River Laboratories International by 1,366.7% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 24,846 shares of the medical research company's stock valued at $3,740,000 after buying an additional 23,152 shares during the period. Groupe la Francaise raised its holdings in Charles River Laboratories International by 44.6% during the 1st quarter. Groupe la Francaise now owns 590 shares of the medical research company's stock valued at $89,000 after buying an additional 182 shares during the period. Compound Planning Inc. raised its holdings in Charles River Laboratories International by 16.4% during the 1st quarter. Compound Planning Inc. now owns 1,879 shares of the medical research company's stock valued at $283,000 after buying an additional 265 shares during the period. Ameriprise Financial Inc. raised its holdings in Charles River Laboratories International by 144.3% during the 1st quarter. Ameriprise Financial Inc. now owns 544,825 shares of the medical research company's stock valued at $82,007,000 after buying an additional 321,789 shares during the period. Finally, Norinchukin Bank The raised its holdings in Charles River Laboratories International by 13.3% during the 1st quarter. Norinchukin Bank The now owns 2,554 shares of the medical research company's stock valued at $384,000 after buying an additional 299 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Up 0.0%

Charles River Laboratories International stock traded up $0.07 during mid-day trading on Monday, reaching $163.29. 860,239 shares of the company were exchanged, compared to its average volume of 956,203. The business has a fifty day moving average of $159.63 and a 200 day moving average of $148.82. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The firm has a market cap of $8.04 billion, a P/E ratio of -122.77, a PEG ratio of 5.22 and a beta of 1.47. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International's revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.80 earnings per share. Research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president directly owned 24,116 shares of the company's stock, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Evercore ISI increased their price target on Charles River Laboratories International from $180.00 to $190.00 and gave the company an "outperform" rating in a report on Friday, August 8th. JPMorgan Chase & Co. boosted their price objective on Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a research note on Wednesday, May 14th. Finally, Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $188.00 to $182.00 in a research note on Friday, May 23rd. Five research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $175.69.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).